European leadership HRA Pharma is a European leader in emergency contraception and compromised skin, with distribution across 11 countries and availability in over 71 markets through partnerships, presenting a strong platform for expansion through co-marketing, licensing, or strategic alliances with complementary consumer healthcare brands.

Rx to OTC momentum The company has ambitious Rx-to-OTC switches in the pipeline, creating opportunities to collaborate on regulatory support, co-development, or channel expansion for new over‑the‑counter products targeting unmet user needs.

Acquisition and scale Recent and historical acquisitions, including Merz portfolio expansion and asset integration, indicate a readiness to accelerate growth via portfolio diversification, clinical science partnerships, and OEM or contract manufacturing collaborations for speed to market.

Global reach, local focus Direct operations in 11 European countries with partnerships extending to 71 countries signal strong regional footprint coupled with a need for localized marketing, logistics optimization, and digital health solutions to support cross-border product launches.

Financially lean growth With revenue in the lower mid range and a track record of high-velocity product launches, there is opportunity to engage in value-added partnerships, co-funding of strategic product campaigns, and scalable distribution deals to capitalize on rapid growth trajectories.